AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
AnaptysBio, a clinical-stage biotechnology company focused on antibody development, announced that CEO Hamza Suria will present at the 2020 Cantor Global Virtual Healthcare Conference on September 17, 2020, at 12:00 p.m. ET. The presentation will be accessible online, with a replay available for 90 days post-event. AnaptysBio's pipeline includes anti-IL-36R antibody imsidolimab and anti-IL-33 antibody etokimab, targeting rare inflammatory diseases and chronic conditions. The company employs a proprietary somatic hypermutation platform for antibody discovery.
- None.
- None.
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17, 2020 at 12:00 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://www.webcaster4.com/Webcast/Page/2495/37348
A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https://www.anaptysbio.com. A replay of the webcast will be available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi-mediated skin toxicities and ichthyosis; its anti-IL-33 antibody etokimab, previously referred to as ANB020, for the treatment of chronic rhinosinusitis with nasal polyps, or CRSwNP, and eosinophilic asthma; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab, GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.
Contact:
Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
dmulroy@anaptysbio.com
FAQ
When will AnaptysBio present at the 2020 Cantor Global Virtual Healthcare Conference?
How can I access the AnaptysBio presentation from the conference?
What are the key products in AnaptysBio's pipeline?
What technology does AnaptysBio use for antibody discovery?